FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084343791> ?p ?o ?g. }

• W2084343791 endingPage "4177" @default.
• W2084343791 startingPage "4168" @default.
• W2084343791 abstract "BACKGROUND: The current study was conducted to evaluate the influence of race/ethnicity and tumor subtype in pathologic complete response (pCR) following treatment with neoadjuvant chemotherapy. METHODS: A total of 2074 patients diagnosed with breast cancer between 1994 and 2008 who were treated with neoadjuvant anthracycline- and taxane-based chemotherapy were included. pCR was defined as no residual invasive cancer in the breast and axilla. The Kaplan-Meier product-limit was used to calculate survival outcomes. Cox proportional hazards models were fitted to determine the relationship of patient and tumor variables with outcome. RESULTS: The median patient age was 50 years; 14.6% of patients were black, were 15.2% Hispanic, 64.3% were white, and 5.9% were of other race. There were no differences in pCR rates among race/ethnicity (12.3% in black, 14.2% in Hispanics, 12.3% in whites, and 11.5% in others, P = .788). Lack of pCR, breast cancer subtype, grade 3 tumors, and lymphovascular invasion were associated with worse recurrence-free survival (RFS) and overall survival (OS) (P ≤ .0001). Differences in RFS by race/ethnicity were noted in the patients with hormone receptor-positive disease (P = .007). On multivariate analysis, Hispanics had improved RFS (hazard ratio [HR], 0.69; 95% confidence interval [95% CI], 0.49-0.97) and OS (HR, 0.63; 95% CI, 0.41-0.97); blacks had a trend toward worse outcomes (RFS: HR, 1.28 [95% CI, 0.97-1.68] and OS: HR, 1.32 [95% CI, 0.97-1.81]) when compared with whites. CONCLUSIONS: In this cohort of patients, race/ethnicity was not found to be significantly associated with pCR rates. On a multivariate analysis, improved outcomes were observed in Hispanics and a trend toward worse outcomes in black patients, when compared with white patients. Further research was needed to explore the potential differences in biology and outcomes. Cancer 2010. © 2010 American Cancer Society." @default.
• W2084343791 created "2016-06-24" @default.
• W2084343791 creator A5001007969 @default.
• W2084343791 creator A5012085802 @default.
• W2084343791 creator A5014713051 @default.
• W2084343791 creator A5018617106 @default.
• W2084343791 creator A5026024346 @default.
• W2084343791 creator A5027028437 @default.
• W2084343791 creator A5039722353 @default.
• W2084343791 creator A5047713528 @default.
• W2084343791 creator A5073488441 @default.
• W2084343791 creator A5080832682 @default.
• W2084343791 date "2010-05-28" @default.
• W2084343791 modified "2023-10-18" @default.
• W2084343791 title "Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy" @default.
• W2084343791 cites W1485092616 @default.
• W2084343791 cites W1964602270 @default.
• W2084343791 cites W1972859881 @default.
• W2084343791 cites W1988470760 @default.
• W2084343791 cites W1995224853 @default.
• W2084343791 cites W1997514136 @default.
• W2084343791 cites W2016095285 @default.
• W2084343791 cites W2023769093 @default.
• W2084343791 cites W2028930298 @default.
• W2084343791 cites W2030401705 @default.
• W2084343791 cites W2056050422 @default.
• W2084343791 cites W2068285828 @default.
• W2084343791 cites W2073206597 @default.
• W2084343791 cites W2076897726 @default.
• W2084343791 cites W2088034629 @default.
• W2084343791 cites W2096145980 @default.
• W2084343791 cites W2101842106 @default.
• W2084343791 cites W2106428582 @default.
• W2084343791 cites W2109462843 @default.
• W2084343791 cites W2120506784 @default.
• W2084343791 cites W2122830295 @default.
• W2084343791 cites W2124719736 @default.
• W2084343791 cites W2133764807 @default.
• W2084343791 cites W2139510434 @default.
• W2084343791 cites W2142413451 @default.
• W2084343791 cites W2151778057 @default.
• W2084343791 cites W2151859419 @default.
• W2084343791 cites W2161426850 @default.
• W2084343791 cites W2164774797 @default.
• W2084343791 cites W2164961968 @default.
• W2084343791 cites W2330495772 @default.
• W2084343791 doi "https://doi.org/10.1002/cncr.25296" @default.
• W2084343791 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2954673" @default.
• W2084343791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20564153" @default.
• W2084343791 hasPublicationYear "2010" @default.
• W2084343791 type Work @default.
• W2084343791 sameAs 2084343791 @default.
• W2084343791 citedByCount "40" @default.
• W2084343791 countsByYear W20843437912012 @default.
• W2084343791 countsByYear W20843437912013 @default.
• W2084343791 countsByYear W20843437912014 @default.
• W2084343791 countsByYear W20843437912015 @default.
• W2084343791 countsByYear W20843437912016 @default.
• W2084343791 countsByYear W20843437912018 @default.
• W2084343791 countsByYear W20843437912020 @default.
• W2084343791 countsByYear W20843437912021 @default.
• W2084343791 countsByYear W20843437912022 @default.
• W2084343791 countsByYear W20843437912023 @default.
• W2084343791 crossrefType "journal-article" @default.
• W2084343791 hasAuthorship W2084343791A5001007969 @default.
• W2084343791 hasAuthorship W2084343791A5012085802 @default.
• W2084343791 hasAuthorship W2084343791A5014713051 @default.
• W2084343791 hasAuthorship W2084343791A5018617106 @default.
• W2084343791 hasAuthorship W2084343791A5026024346 @default.
• W2084343791 hasAuthorship W2084343791A5027028437 @default.
• W2084343791 hasAuthorship W2084343791A5039722353 @default.
• W2084343791 hasAuthorship W2084343791A5047713528 @default.
• W2084343791 hasAuthorship W2084343791A5073488441 @default.
• W2084343791 hasAuthorship W2084343791A5080832682 @default.
• W2084343791 hasBestOaLocation W20843437912 @default.
• W2084343791 hasConcept C121608353 @default.
• W2084343791 hasConcept C126322002 @default.
• W2084343791 hasConcept C143998085 @default.
• W2084343791 hasConcept C207103383 @default.
• W2084343791 hasConcept C2776694085 @default.
• W2084343791 hasConcept C2776802502 @default.
• W2084343791 hasConcept C2777511904 @default.
• W2084343791 hasConcept C44249647 @default.
• W2084343791 hasConcept C50382708 @default.
• W2084343791 hasConcept C530470458 @default.
• W2084343791 hasConcept C71924100 @default.
• W2084343791 hasConceptScore W2084343791C121608353 @default.
• W2084343791 hasConceptScore W2084343791C126322002 @default.
• W2084343791 hasConceptScore W2084343791C143998085 @default.
• W2084343791 hasConceptScore W2084343791C207103383 @default.
• W2084343791 hasConceptScore W2084343791C2776694085 @default.
• W2084343791 hasConceptScore W2084343791C2776802502 @default.
• W2084343791 hasConceptScore W2084343791C2777511904 @default.
• W2084343791 hasConceptScore W2084343791C44249647 @default.
• W2084343791 hasConceptScore W2084343791C50382708 @default.
• W2084343791 hasConceptScore W2084343791C530470458 @default.
• W2084343791 hasConceptScore W2084343791C71924100 @default.
• W2084343791 hasIssue "17" @default.

• next